Medicure Inc Total Liabilities
Medicure Inc total liabilities. Based on the latest financial reports, Medicure Inc (MPH) has total liabilities worth CA$11.02 Million CAD (≈ $7.97 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Medicure Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Medicure Inc (2000–2025)
Total liabilities of Medicure Inc from 2000 to 2025. This chart illustrates how Medicure Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Medicure Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Medicure Inc Competitors by Total Liabilities
The table below lists competitors of Medicure Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UFO Moviez India Limited
NSE:UFO
|
India | Rs-3.25 Billion |
|
Seni Jaya Corporation Bhd
KLSE:9431
|
Malaysia | RM73.50 Million |
|
Pritika Auto Industries Limited
NSE:PRITIKAUTO
|
India | Rs3.00 Billion |
|
Thai Rubber Latex Group Public Company Limited
BK:TRUBB
|
Thailand | ฿4.73 Billion |
|
GLORY HEALTH IND. HD-001
F:84R
|
Germany | €43.59 Billion |
|
Ajinextek Co. Ltd
KQ:059120
|
Korea | ₩4.40 Billion |
|
Far East Gold Ltd
AU:FEG
|
Australia | AU$1.21 Million |
|
Inspira Technologies Oxy BHN Ltd
NASDAQ:IINN
|
USA | $3.17 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Medicure Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Medicure Inc total assets.
Liquidity & Leverage Metrics
Medicure Inc Total Liabilities Ratios Explained
Medicure Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medicure Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medicure Inc (2000–2025)
The table below shows the annual total liabilities of Medicure Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$12.04 Million ≈ $8.71 Million |
+35.27% |
| 2024-12-31 | CA$8.90 Million ≈ $6.44 Million |
+9.04% |
| 2023-12-31 | CA$8.16 Million ≈ $5.90 Million |
-8.21% |
| 2022-12-31 | CA$8.89 Million ≈ $6.43 Million |
-11.04% |
| 2021-12-31 | CA$10.00 Million ≈ $7.23 Million |
-32.94% |
| 2020-12-31 | CA$14.91 Million ≈ $10.78 Million |
-2.83% |
| 2019-12-31 | CA$15.34 Million ≈ $11.10 Million |
-23.93% |
| 2018-12-31 | CA$20.17 Million ≈ $14.59 Million |
-58.18% |
| 2017-12-31 | CA$48.22 Million ≈ $34.88 Million |
-72.56% |
| 2016-12-31 | CA$175.77 Million ≈ $127.15 Million |
+946.52% |
| 2015-12-31 | CA$16.80 Million ≈ $12.15 Million |
+60.39% |
| 2014-12-31 | CA$10.47 Million ≈ $7.57 Million |
+10.41% |
| 2013-12-31 | CA$9.48 Million ≈ $6.86 Million |
+22.37% |
| 2012-12-31 | CA$7.75 Million ≈ $5.61 Million |
+18.07% |
| 2011-12-31 | CA$6.56 Million ≈ $4.75 Million |
-79.53% |
| 2010-12-31 | CA$32.07 Million ≈ $23.20 Million |
+3.68% |
| 2009-12-31 | CA$30.93 Million ≈ $22.37 Million |
+6.30% |
| 2008-12-31 | CA$29.10 Million ≈ $21.05 Million |
-29.65% |
| 2007-12-31 | CA$41.36 Million ≈ $29.92 Million |
+62.33% |
| 2006-12-31 | CA$25.48 Million ≈ $18.43 Million |
+1449.52% |
| 2005-12-31 | CA$1.64 Million ≈ $1.19 Million |
-39.83% |
| 2004-12-31 | CA$2.73 Million ≈ $1.98 Million |
+234.25% |
| 2003-12-31 | CA$817.57K ≈ $591.42K |
+131.01% |
| 2002-12-31 | CA$353.91K ≈ $256.01K |
-9.18% |
| 2001-12-31 | CA$389.66K ≈ $281.88K |
-31.65% |
| 2000-12-31 | CA$570.08K ≈ $412.38K |
-- |
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more